NasdaqGS:BEAMBiotechs
Beam Therapeutics (BEAM) On A Wider Q2 Loss And The Valuation Debate
Beam Therapeutics (BEAM) reported second quarter 2026 results that showed a wider net loss and higher loss per share, which has become a key focus for investors assessing the stock this week.
See our latest analysis for Beam Therapeutics.
Despite the wider quarterly loss, Beam Therapeutics has seen a sharp 1 day share price return of 9.42% and a 7 day share price return of 7.84%. However, the 30 day share price return is down 18.51% and the 90 day share price return is down 12.34%. At the...